知识与财富的链接
目的观察抗疏强骨合剂结合基础抗骨质疏松药物对原发性骨质疏松症的临床有效性及安全性,探讨其应用前景。方法174例原发性骨质疏松症患者随机分为治疗组和对照1组、对照2组,每组各58例。治疗组给予抗疏强骨合剂、碳酸钙D3片、阿仑膦酸钠片治疗,对照1组单纯给予碳酸钙D3片、阿仑膦酸钠片治疗,对照2组给予仙灵骨葆胶囊、碳酸钙D3片、阿仑膦酸钠片治疗,连续服用6个月后观察并分析各组治疗前后中医证候积分、骨密度值、骨代谢生化指标改善情况。结果(1)治疗组在中医证候疗效评价中总有效率为8718%,优于对照1组(6667%)(P005),与对照2组(8205%)比较无明显差异(P005);在主证单项症状和次症状单项症状改善情况中,治疗组明显优于对照1组和对照2组(P005)。(2)3种治疗方法均能改善患者腰椎及股骨颈部位的骨密度,但治疗组的效果更佳,更能提高患者的骨密度,与对照1组和对照2组比较差异有统计学意义(P005)。(3)治疗组能改善患者骨转换指标,治疗前后比较差异有统计学意义(P005)。结论抗疏强骨合剂结合基础抗骨质疏松药物治疗原发性骨质疏松症疗效确切,能改善患者中医证候积分,增加患者骨密度,促进骨形成,降低骨吸收,改善骨代谢,起到防治骨质疏松症的作用。
Objective To observe the clinical efficacy and safety of anti-osteoporosis and bone strengthening mixture combined with basic anti-osteoporosis drugs in primary osteoporosis, and to explore its application prospects. Methods A total of 174 patients with primary osteoporosis were randomly divided into treatment group, control group 1, and control group 2, with 58 cases in each group. Patients in the treatment group received anti-osteoporosis and bone strengthening mixture, calcium carbonate D3 tablets, and alendronate sodium tablets. Patients in the control group 1 received calcium carbonate D3 tablets and alendronate sodium tablets. Patients in the control group 2 received Xianlinggubao capsules, calcium carbonate D3 tablets, and alendronate sodium tablets. After 6 months of continuous observation, the changes of TCM syndrome scores, bone mineral density, and bone metabolic and biochemical indicators before and after the treatment were analyzed. Results (1) The total effective rate of the treatment group in the evaluation of TCM syndromes was 87.18%, which was better than that of the control group (66.67%, P<0.05), and there was no significant difference compared with the control group 2 (82.05%, P>0.05). In the improvement of single symptom and sub-symptoms, the treatment group was significantly better than the control group 1 and the control group 2 (P<0.05). (2) All the three treatment methods improved bone mineral density of the lumbar spine and the femoral neck. The treatment group had better effect in improving the bone mineral density of the patients. Compared with the control group 1 and the control group 2, there was significant difference (P<0.05). (3) The treatment group improved the bone turnover index of the patients, and there was significant difference before and after treatment (P<0.05). Conclusion Anti-osteoporosis and bone strengthening mixture is effective in the treatment of primary osteoporosis. It improves TCM syndrome scores, increases bone mineral density, promotes bone formation, reduces bone resorption, improves bone metabolism, and prevents osteoporosis.
